[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342040-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342040-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","chrdl1-inhibits-oscc-metastasis-via-mapk-signaling-mediated-inhibition-of-med29","CHRDL1 inhibits OSCC metastasis via MAPK signaling-mediated inhibition of MED29","","CHRDL1 belongs to a novel class of mRNA molecules, yet its biological roles in oral squamous cell carcinoma (OSCC) remain insufficiently defined. The study evaluates MED29 mRNA and protein expression in OSCC using RT-qPCR, immunohistochemistry, Western blotting, and multiple functional assays. Data indicate MED29 upregulation in OSCC and its association with enhanced EMT, migration, and invasion. CHRDL1 suppresses MED29, thereby restraining EMT progression and reducing invasion and migration via MAPK signaling inhibition, supported by in vivo metastasis modeling.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/chrdl1-inhibits-oscc-metastasis-via-mapk-signaling-mediated-inhibition-of-med29/342040/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/chrdl1-inhibits-oscc-metastasis-via-mapk-signaling-mediated-inhibition-of-med29/342040.png","ImageObject",300,407,{"name":42,"@type":43},"Skyler","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does MED29 play in OSCC in this study?","Question",{"text":63,"@type":64},"MED29 expression is elevated in OSCC tumor tissues and is linked to increased migration and invasion. MED29 overexpression promotes EMT, while knockdown blocks EMT and reduces migration and invasion.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does CHRDL1 affect MED29 and OSCC malignancy?",{"text":68,"@type":64},"CHRDL1 inhibits MED29 expression, suppressing EMT progression. This results in restrained invasion and migration of OSCC cells through MED29 regulation.",{"name":70,"@type":61,"acceptedAnswer":71},"Which signaling pathway is implicated in CHRDL1’s anti-metastatic effect?",{"text":72,"@type":64},"The study concludes that CHRDL1 inhibits invasion and metastasis by suppressing the MAPK signaling pathway via MED29 inhibition.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342040,1790813472,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Huang et al. Molecular Medicine (2024) 30:187 [https://doi.org/10.1186/s10020-024-00956-y](https://doi.org/10.1186/s10020-024-00956-y)  \nMolecular Medicine  \n RESEARCH ARTICLE Open Access  \nCHRDL1 inhibits OSCC metastasis via MAPK signaling-mediated inhibition of MED29  \nSongkai Huang1†, Junwei Zhang1†, Yu Qiao2, Janak Lal Pathak 1, Rui Zou1, ZhengGuo Piao 1, ShiMin Xie1, Jun Liang2* and Kexiong Ouyang1*  \nAbstract  \nBackground CHRDL1 belongs to a novel class of mRNA molecules. Nonetheless, the specific biological functions and underlying mechanisms of CHRDL1 in oral squamous cell carcinoma (OSCC) remain largely unexplored.  \nMethods RT-qPCR and immunohistochemical staining were employed to assess the mRNA and protein expression levels of the MED29 gene in clinical samples of OSCC. Additionally, RT-qPCR and Western Blot analyses were conducted to investigate the mRNA and protein expression levels of the MED29 gene specifically in OSCC. The impact of MED29 on epithelial-mesenchymal transition (EMT), invasion, and migration of OSCC was evaluated through scratch assay, transwell assay, and immunofluorescence staining. Furthermore, wound healing assay and Transwell assay were utilized to examine whether CHRDL1 influences the malignant behavior of OSCC by modulating MED29 in vitro. The regulatory role of CHRDL1 on MED29 was further elucidated in vivo through a tail vein lung metastasis model in nude mice.  \nResults MED29 expression was elevated in tumor tissues of OSCC patients compared with adjacent cancer tissues. Moreover, in CAL27 and SCC25 cell lines, MED29 was upregulated and associated with increased cell migration and invasion abilities. Overexpression of MED29 facilitated EMT in OSCC cell lines, whereas knockdown of MED29 impeded EMT, resulting in diminished cell migration and invasion capacities. CHRDL1 exerted inhibitory effects on the expression of MED29, thereby suppressing EMT progression and consequently restraining the invasion and migration of OSCC cells. Furthermore, CHRDL1 mediated the inhibition of migration of OSCC cell lines to the OSCC through its regulation of MED29 .  \nConclusions MED29 facilitated the epithelial-mesenchymal transition process in OSCC, thereby promoting migration and invasion. On the other hand, CHRDL1 exerted inhibitory effects on the invasion and metastasis of OSCC by suppressing MED29 through the inhibition of the MAPK signaling pathway.  \nKeywords MED29, CHRDL1, OSCC, EMT  \n†Songkai Huang and Junwei Zhang have contributed equally to this work and share first authorship.  \n*Correspondence: Jun Liang [liangjun@mail.sysu.edu.cn](liangjun@mail.sysu.edu.cn)[ ](liangjun@mail.sysu.edu.cn)Kexiong Ouyang [ouyangkexiong@163.com](ouyangkexiong@163.com)  \n1 School and Hospital of Stomatology, Guangdong Engineering Research Center of Oral Restoration and Reconstruction, Guangzhou Key Laboratory of Basic and Applied Research of Oral Regenerative Medicine, Guangzhou Medical University, Guangzhou 510182, China  \n2 Department of Stomatology, The Seventh Affiliated Hospital, SunYatSsen University, Shenzhen 518000, Guangdong, China  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativ","cbCaiarUmpCcBXJg","https://ap.wps.com/l/cbCaiarUmpCcBXJg","pdf",2564181,14,"English","# Abstract\n# Introduction\n## OSCC background and clinical need\n## EMT and invasion/metastasis mechanisms","[{\"question\":\"What role does MED29 play in OSCC in this study?\",\"answer\":\"MED29 expression is elevated in OSCC tumor tissues and is linked to increased migration and invasion. MED29 overexpression promotes EMT, while knockdown blocks EMT and reduces migration and invasion.\"},{\"question\":\"How does CHRDL1 affect MED29 and OSCC malignancy?\",\"answer\":\"CHRDL1 inhibits MED29 expression, suppressing EMT progression. This results in restrained invasion and migration of OSCC cells through MED29 regulation.\"},{\"question\":\"Which signaling pathway is implicated in CHRDL1’s anti-metastatic effect?\",\"answer\":\"The study concludes that CHRDL1 inhibits invasion and metastasis by suppressing the MAPK signaling pathway via MED29 inhibition.\"}]","CHRDL1 inhibits OSCC metastasis via MAPK signaling-mediated inhibition of MED29 | PDF",1790044863,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/33f711b47de69691554c3a1f712137eb.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/240f87d7faeb8093049aa8ea5d63d190.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fb2ee160234bc385c36d84106f54ecc4.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/214ff965dab9e6e79c43ae878d237f45.webp",980,1301]